2022年6月1日
TgMab-2: An Anti-human T Cell Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibitory Motif Domain Monoclonal Antibody for Immunocytochemistry
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
- ,
- ,
- ,
- 巻
- 41
- 号
- 3
- 開始ページ
- 157
- 終了ページ
- 162
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1089/mab.2022.0013
- 出版者・発行元
- Mary Ann Liebert Inc
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is one of the immune checkpoint molecules. TIGIT is expressed in T or natural killer (NK) cells and is upregulated in several cancers. Because TIGIT suppresses the antitumor activity of the T or NK cells by binding to its ligand, such as CD155, CD112, and CD113, TIGIT can be a molecular marker or a therapeutic target for cancer immunotherapy. We previously developed an anti-human TIGIT (hTIGIT) monoclonal antibody (mAb; clone TgMab-2; mouse IgG1, kappa) by the Cell-Based Immunization and Screening method. TgMab-2 binds to hTIGIT with high binding affinity in flow cytometry. In this study, we investigated the availability of TgMab-2 and its recombinant mAb (recTgMab-2) in immunocytochemistry. We found that TgMab-2 and recTgMab-2 bind to hTIGIT-overexpressed Chinese hamster ovary (CHO)-K1 cells, but not parental CHO-K1 cells, indicating that both mAbs specifically recognize hTIGIT. Furthermore, both mAbs recognized endogenous hTIGIT expressed in human NK cells in immunocytochemistry. These results demonstrate that TgMab-2 and recTgMab-2 are applicable for immunocytochemistry against hTIGIT.
- リンク情報
- ID情報
-
- DOI : 10.1089/mab.2022.0013
- eISSN : 2167-9436
- PubMed ID : 35736625